FibroGen Announces FDA Advisory Committee to Review Roxadustat New Drug Application Tentatively Scheduled for July 15, 2021
FREE Breaking News Alerts from StreetInsider.com!
StreetInsider.com Top Tickers, 4/24/2024
- S&P 500 ends higher as markets weigh rising yields, upbeat corporate results
- Meta Platforms reports softer Q2 revenue guidance on plans to boost spending on AI
- IBM (IBM) announces mixed Q1 results, HashiCorp acquisition; shares down
- Equities mixed as investors eye earnings; yen on intervention watch
- ServiceNow (NOW) stock falls as refreshed subscription outlook trails estimates
- Fisker (FSR) Appoints Michael Healy as Chief Restructuring Officer
- Seagate Technology (STX) Enters $600M Asset Purchase Agreement with Avago
- Meta Platforms (META) Tops Q1 EPS by 39c, Offers Guidance
- Hasbro (HAS) brand strength sees earnings top expectations
- IBM (IBM) announces mixed Q1 results, HashiCorp acquisition; shares down
- After-hours movers: Meta, Ford, IBM, ServiceNow and more
- Midday movers: Tesla, Boeing rise; Uber, Old Dominion Freight fall
- After-hours movers: Tesla, Texas Instruments, Seagate, Visa and more
- Midday movers: PepsiCo, JetBlue fall; GM, Danaher and UPS rise
- After-hours movers: Cadence Design Systems, Cleveland-Cliffs, Riot Platforms, and more
FibroGen (FGEN) PT Lowered to $55 at Stifel
April 7, 2021 7:49 AM EDTStifel analyst Annabel Samimy lowered the price target on FibroGen (NASDAQ: FGEN) to $55.00 (from $70.00) while maintaining a Buy rating.
The analyst commented, "FGENs clarification of a different Roxadustat cardiovascular safety analysis is another unpleasant surprise, but it is not clear that it changes the... More
Mizuho Securities Downgrades FibroGen (FGEN) to Neutral
April 7, 2021 6:30 AM EDTMizuho Securities analyst Difei Yang downgraded FibroGen (NASDAQ: FGEN) from Buy to Neutral with a price target of $29.00.
The analyst comments "We are downgrading FGEN shares to Neutral, and reducing our PT from $72 to $29 as we see higher risk and uncertainty around timelines to... More
